These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18164193)

  • 1. Opioid dependent patients' experiences of and attitudes towards having their injecting sites examined.
    Winstock AR; Nittis M; Whitton G; Lea T
    Int J Drug Policy; 2009 Jan; 20(1):85-9. PubMed ID: 18164193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
    Madden A; Lea T; Bath N; Winstock AR
    Drug Alcohol Rev; 2008 Nov; 27(6):671-8. PubMed ID: 19378450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug injecting in patients in New Zealand Methadone Maintenance Treatment programs: an anonymous survey.
    Judson G; Bird R; O'Connor P; Bevin T; Loan R; Schroder M; McGrath R; Weatherall M; Moriarty H; Robinson G
    Drug Alcohol Rev; 2010 Jan; 29(1):41-6. PubMed ID: 20078681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
    Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
    J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Persistent injecting practices in subjects on methadone or buprenorphine maintenance therapy. A study of 600 cases].
    Fontaa V; Bronner C
    Ann Med Interne (Paris); 2001 Nov; 152 Suppl 7():59-69. PubMed ID: 11965100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription opioid abuse among enrollees into methadone maintenance treatment.
    Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
    Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is groin injecting an ethical boundary for harm reduction?
    Miller PG; Lintzeris N; Forzisi L
    Int J Drug Policy; 2008 Dec; 19(6):486-91. PubMed ID: 18024001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
    Winstock AR; Lea T; Sheridan J
    Drug Alcohol Rev; 2008 Jul; 27(4):393-7. PubMed ID: 18584389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine injection in Melbourne, Australia--an update.
    Aitken CK; Higgs PG; Hellard ME
    Drug Alcohol Rev; 2008 Mar; 27(2):197-9. PubMed ID: 18264882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
    Winstock AR; Lintzeris N; Lea T
    Int J Drug Policy; 2011 Jan; 22(1):77-81. PubMed ID: 20956077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
    Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
    Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs.
    Islam MM; Topp L; Iversen J; Day C; Conigrave KM; Maher L
    Aust N Z J Public Health; 2013 Apr; 37(2):148-54. PubMed ID: 23551473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.
    Lawrinson P; Roche A; Terao H; Le PP
    Drug Alcohol Rev; 2008 Jan; 27(1):47-53. PubMed ID: 18034381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment: implications for new approaches in harm reduction and care.
    Gervasoni JP; Balthasar H; Huissoud T; Jeannin A; Dubois-Arber F
    Int J Drug Policy; 2012 Jan; 23(1):33-6. PubMed ID: 21705205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.
    Lavie E; Fatséas M; Denis C; Auriacombe M
    Drug Alcohol Depend; 2009 Jan; 99(1-3):338-44. PubMed ID: 18824311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.